Synthes outshines Stryker in prosperous Q2
This article was originally published in Clinica
Swiss orthopaedics firm Synthes has surpassed analysts’ expectations by posting growth on both its top- and bottom-lines during the second quarter of 2009. The firm’s rival in the orthopaedics space, Stryker, was unable to match this performance, reporting lower sales and decreased net income compared to the same period the previous year.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals